HIGHLIGHTS
- who: Sitagliptin and colleagues from the (UNIVERSITY) have published the research: Original Article, in the Journal: (JOURNAL)
- what: The aim of any drug delivery system is to achieve the desired concentration of the drug in blood or tissue which is therapeutically effective and nontoxic for a prolonged period. is a dipeptidyl peptidase 4 enzyme inhibitor used in the treatment of non-insulin-dependent diabetes mellitus. The aim of this study was to design a flexible dosage form that controls the and provides therapeutic effects with minimum side effects. The research in orally active candidates is . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.